Investing.com - Baird downgraded ResMed (NYSE:RMD) from Outperform to Neutral on Tuesday, while lowering its price target to $275.00 from $300.00. Interestingly, this new target aligns closely with ...
Investing.com - UBS raised its price target on ResMed (NYSE:RMD) to $345.00 from $335.00 on Friday, while maintaining a Buy rating on the medical equipment manufacturer’s stock. The new target ...
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...
Resmed (NYSE: RMD) + announced today that it received FDA clearance for its Smart Comfort personalized therapy offering. San Diego–based Resmed calls Smart Comfort (which was submitted to the FDA as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback